Senate Files

Bills

S. 932 119th Congress

Give Kids a Chance Act of 2025

Latest action, Mar 11, 2025: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

20 cosponsors

Sponsored by Markwayne Mullin (Republican). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
10 D · 10 R
  • Democrat
  • Republican
  • Independent
20 senators cosponsoring

Referred to: Senate: Health, Education, Labor, and Pensions Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

53 clientsQ1 2025Q3 2026

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

CURE SMA
7 reports
HEALTHCARE INSTITUTE OF NEW JERSEY
7 reports
IONIS PHARMACEUTICALS, INC.
7 reports
TRAVERE THERAPEUTICS
7 reports
ACADIA PHARMACEUTICALS
6 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)
ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
6 reports
IONIS PHARMACEUTICALS, INC.
LMH STRATEGIC SOLUTIONS
6 reports
MIGHTY THERAPEUTICS (FMRLY STEALTH BIOTHERAPEUTICS INC.)
6 reports
PTC THERAPEUTICS, INC.
LMH STRATEGIC SOLUTIONS
6 reports
ALLIANCE FOR REGENERATIVE MEDICINE
5 reports
ASSOCIATION FOR CLINICAL ONCOLOGY
5 reports
ASTRAZENECA PHARMACEUTICALS LP
5 reports
BAYER CORPORATION (CONSOLIDATED REPORT)
5 reports
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
5 reports
BRIDGEBIO PHARMA, INC.
5 reports
All 25 of 63 clients
ClientLobbying firmReportsReports totalingFromToSenate
CURE SMA7$525KQ1 2025Q3 2026yes
HEALTHCARE INSTITUTE OF NEW JERSEY7$333KQ1 2025Q3 2026yes
IONIS PHARMACEUTICALS, INC.7$910KQ1 2025Q3 2026yes
TRAVERE THERAPEUTICS7$1.2MQ1 2025Q3 2026yes
ACADIA PHARMACEUTICALS6$3.6MQ4 2025Q3 2026yes
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)6$360KQ1 2025Q2 2026yes
IONIS PHARMACEUTICALS, INC.LMH STRATEGIC SOLUTIONS6$0Q4 2025Q3 2026yes
MIGHTY THERAPEUTICS (FMRLY STEALTH BIOTHERAPEUTICS INC.)6$620KQ1 2025Q2 2026yes
PTC THERAPEUTICS, INC.LMH STRATEGIC SOLUTIONS6$0Q4 2025Q3 2026yes
ALLIANCE FOR REGENERATIVE MEDICINE5$790KQ1 2025Q1 2026yes
ASSOCIATION FOR CLINICAL ONCOLOGY5$1.3MQ1 2025Q1 2026yes
ASTRAZENECA PHARMACEUTICALS LP5$7.4MQ1 2025Q1 2026yes
BAYER CORPORATION (CONSOLIDATED REPORT)5$11.2MQ1 2025Q1 2026yes
BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)5$2.0MQ1 2025Q1 2026yes
BRIDGEBIO PHARMA, INC.5$1.6MQ1 2025Q1 2026yes
CHIESI USA, INC.SPLITOAK STRATEGIES LLC5$0Q1 2025Q1 2026yes
LIFE SCIENCES PENNSYLVANIA5$6,000Q4 2025Q3 2026yes
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.)NATIONAL ASSOCIATION OF CHILDRENS HOSPITALS AND AFFILIATES5$7.6MQ4 2025Q3 2026yes
PATIENTS RISING NOWYC CONSULTING, LLC5$200KQ1 2025Q1 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA5$50.1MQ1 2025Q1 2026yes
PRAXIS PRECISION MEDICINESTHE KPM GROUP DC LLC5$200KQ1 2025Q1 2026yes
PTC THERAPEUTICS, INC.5$1.0MQ1 2025Q1 2026yes
RARE DISEASE COMPANY COALITION5$400KQ1 2025Q1 2026yes
RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES)5$220KQ1 2025Q1 2026yes
ULTRAGENYX PHARMACEUTICAL, INC.MEHLMAN CONSULTING, INC.5$0Q1 2025Q1 2026yes